Parameters | Univariate analysis | Multivariate analysis | ||
---|---|---|---|---|
HR (95% CI) | P | HR (95% CI) | P | |
Age (≤ 49 vs. > 49) | 1.08 (0.79–1.48) | 0.638 |  |  |
Position (left vs. right) | 0.92 (0.66–1.27) | 0.602 |  |  |
BMI (< 24 vs. ≥ 24) | 1.3 (0.94–1.79) | 0.109 |  |  |
Height (≤ 1.6 vs. > 1.6) | 0.93 (0.67–1.28) | 0.648 |  |  |
Weight (≤ 61.5 vs. > 61.5) | 1.29 (0.93–1.77) | 0.123 |  |  |
Menopause (no vs. yes) | 1.22 (0.89–1.68) | 0.218 |  |  |
Preneoadjuvant chemotherapy hematological parameters | ||||
 mSIS (high risk vs. low risk) | 0.72 (0.50–1.04) | 0.078 |  |  |
 SIS (high risk vs. low risk) | 1.10 (0.75–1.60) | 0.629 |  |  |
 NLR (≤ 2.24 vs. > 2.24) | 1.39 (1–1.94) | 0.052 |  |  |
 LMR (≤ 2.96 vs. > 2.96) | 0.6 (0.38–0.95) | 0.028 | 0.57 (0.36–0.89) | 0.0142 |
 Lymphocyte (≤ 1.96 vs. > 1.96) | 0.97 (0.7–1.33) | 0.834 |  |  |
 Neutrophil (≤ 3.76 vs. > 3.76) | 1 (0.73–1.37) | 0.992 |  |  |
 Monocyte (≤ 0.41 vs. > 0.41) | 0.91 (0.66–1.25) | 0.557 |  |  |
 Hemoglobin (≤ 135.4 vs. > 135.4) | 0.66 (0.48–0.91) | 0.012 | 0.78 (0.55–1.10) | 0.1550 |
 Platelet (≤ 242 vs. > 242) | 0.98 (0.71–1.35) | 0.907 |  |  |
 Albumin (≤ 46.3 vs. > 46.3) | 1.2 (0.84–1.7) | 0.32 |  |  |
 Globulin (≤ 30 vs. > 30) | 1 (0.73–1.38) | 1 |  |  |
 Clinical T stage (1 vs. 2) | 0.82 (0.51–1.33) | 0.417 |  |  |
 Clinical T stage (1 vs. 3) | 1.11 (0.64–1.95) | 0.707 |  |  |
 Clinical T stage (1 vs. 4) | 2.39 (0.81–7) | 0.113 |  |  |
 Clinical N stage (0 vs. 1) | 2.48 (0.83–7.38) | 0.102 |  |  |
 Clinical N stage (0 vs. 2) | 1.75 (0.64–4.78) | 0.273 |  |  |
 Clinical N stage (0 vs. 3) | 2.5 (0.9–6.96) | 0.08 |  |  |
 Clinical TNM stage (I + II vs. III) | 1 (0.62–1.62) | 0.994 |  |  |
 Subtype (luminal A vs. B) | 1.23 (0.73–2.06) | 0.438 |  |  |
 Subtype (luminal A vs. HER-2 OE) | 1.04 (0.58–1.84) | 0.904 |  |  |
 Subtype (luminal A vs. TNBC) | 1.1 (0.61–1.98) | 0.761 |  |  |
 ER (negative vs. positive) | 1.05 (0.76–1.45) | 0.751 |  |  |
 PR (negative vs. positive) | 1 (0.73–1.38) | 0.981 |  |  |
 HER-2 (negative vs. low expression) | 0.95 (0.64–1.4) | 0.788 |  |  |
 HER-2 (negative vs. positive) | 0.85 (0.58–1.24) | 0.396 |  |  |
 Ki-67 (≤ 14% vs. > 14%) | 0.98 (0.7–1.37) | 0.912 |  |  |
 P53 (negative vs. positive) | 0.86 (0.6–1.23) | 0.409 |  |  |
Post neoadjuvant chemotherapy hematological parameters | ||||
 Lymphocyte (≤ 1.54 vs. > 1.54) | 0.94 (0.68–1.29) | 0.699 |  |  |
 Neutrophil (≤ 3.75 vs. > 3.75) | 1.11 (0.81–1.53) | 0.519 |  |  |
 Monocyte (≤ 0.53 vs. > 0.53) | 0.82 (0.6–1.14) | 0.238 |  |  |
 Hemoglobin (≤ 117 vs. > 117) | 0.69 (0.5–0.95) | 0.025 | 0.75 (0.53–1.06) | 0.0982 |
 Platelet (≤ 271 vs. > 271) | 1.07 (0.78–1.47) | 0.672 |  |  |
 Albumin (≤ 46.3 vs. > 46.3) | 0.96 (0.62–1.49) | 0.855 |  |  |
 Globulin (≤ 28 vs. > 28) | 0.82 (0.6–1.14) | 0.239 |  |  |
 Cycle (< 4 vs. ≥ 4) | 0.93 (0.59–1.46) | 0.746 |  |  |
 pCR (no vs. yes) | 0.44 (0.27–0.73) | 0.001 | 0.43 (0.26–0.72) | 0.0013 |